Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatme... 23/11/2023 Healthcare Access to innovation Partners - Almirall
Celtarys Research, a startup developing innovative chemical biology solutions, participate... 21/11/2023 Healthcare Access to innovation Partners - Celtarys Research
BCN HEALTH has presented several communications at the EASL and AASLD congresses evaluatin... 20/11/2023 Healthcare Access to innovation BCN HEALTH has participated in the EASL and AASLD congresses with several communications that have reported on the... Partners - BCN Health
Science and Innovation, the Pending Subject of Spain and a Weak Point in the Progress towa... 10/11/2023 Healthcare Access to innovation Climate change Agrifood Industrial biotechnology Financing Talento Spain needs a clear regulatory framework and support for the biotechnological industry with long-term investments... AseBio
Science and Innovation, the Pending Subject of Spain and a Weak Point in the Progress towa... 10/11/2023 Beyond the direct impact of biotechnology on human health and the planet, investment in science and biotechnology has a... AseBio
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases 07/11/2023 Healthcare Access to innovation Lead candidate KYN-5356, a first-in-class small Molecule KAT-II inhibitor advancing toward the clinic for cognitive... Partners - Ysios Capital Partners
ORYZON announces Last Patient Last Visit in its Phase IIb PORTICO study for Borderline Per... 07/11/2023 Healthcare Access to innovation Innovative drugs Multiple primary endpoints include reduction in agitation and aggression and overall BPD disease improvement. Partners - Oryzon Genomics
Nanodecal Embarks on New Funding Round to Manufacture their Rapid Test for Superbug Detect... 31/10/2023 Healthcare Access to innovation Personalized medicine Antibiotic resistance Financing Nanodecal's funding round aims to raise €600,000 to support the development of a rapid test for detecting respiratory... Partners
ORYZON reports financial results and corporate updates for quarter ended September 30, 202... 30/10/2023 Healthcare Access to innovation Financing Corporate Research and development (R&D) expenses of $3.8 and $12.2 million for the quarter and nine months ended September 30... Partners - Oryzon Genomics
VIVEbiotech has received the "Business Innovation" award at the XXXII edition of the Basqu... 24/10/2023 Healthcare Innovative drugs Personalized medicine Advanced therapies VIVEbiotech has received the "Innovacion Empresarial/Business Innovation" award at the XXXII edition of the La Noche de... Partners - VIVEbiotech
